Viral Vector Manufacturing Market Poised to Reach USD 3.46 Billion by 2032 | Persistence Market Research

The global viral vector manufacturing market has witnessed significant growth, recording a historic CAGR of 12.8% between 2012 and 2021. In 2022, the market was valued at US$ 624.7 Mn, and it is projected to surge ahead at a CAGR of 18.7%, reaching US$ 3.46 Bn by 2032. The demand for viral vectors is primarily driven by their increasing use in gene therapy, vaccine development, and T-cell engineering for cancer treatment. Among various vector types, adeno-associated viral vectors secured a notable market value of US$ 209.6 Mn in 2021.

North America is the leading regional market, driven by the presence of major manufacturers and extensive research in gene-modified cell-based therapeutics. The gene therapy segment dominates in applications, owing to the rising prevalence of genetic disorders and increasing adoption of advanced medical treatments.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response):
https://www.persistencemarketresearch.com/samples/26923

Key Highlights from the Report

The viral vector manufacturing market is projected to grow at a CAGR of 18.7% from 2022 to 2032.

Adeno-associated viral vectors accounted for 38.9% of the market share in 2021.

The gene therapy segment leads the market with 56.7% market share.

The U.S. holds 92.1% of the North American market, driven by the presence of key industry players.

China accounted for 48.2% of the East Asia market and is witnessing rapid expansion in manufacturing capabilities.

Stable expression systems dominate, holding 85.1% market share due to their efficiency in large-scale production.

Market Segmentation

By Virus Type

The viral vector manufacturing market is categorized into adeno-associated viral vectors, lentiviral vectors, retroviral vectors, and others. Among these, adeno-associated viral vectors are the most commonly used due to their ability to efficiently deliver genes into both dividing and non-dividing cells, making them ideal for gene therapy.

By Expression System

The market is segmented into stable and transient expression systems. Stable expression systems dominate with an 85.1% market share due to their high availability and ability to support large-scale therapeutic production. They ensure consistency in process development, making them highly preferred in commercial applications.

Regional Insights

North America

The U.S. leads the global market, accounting for 92.1% of the North American share. The presence of key manufacturers such as Thermo Fisher Scientific, Charles River, and Waisman Biomanufacturing significantly contributes to the region's dominance. The country also benefits from strong R&D initiatives and FDA approvals for gene therapies.

Europe

The U.K. is a key player in Europe, holding 22.9% of the market share in 2021. Research on lentiviral vectors for cancer treatment is a major factor driving market expansion. The increasing focus on CAR T-cell therapy further boosts the market in this region.

Asia-Pacific

China dominates the East Asia market with a 48.2% share, supported by government initiatives and investments in biomanufacturing infrastructure. Expansion projects, such as GenScript ProBio's new viral vector manufacturing facility, indicate strong market potential.

Market Dynamics

Market Drivers

The increasing adoption of gene therapy and cell therapy is a key driver of the viral vector manufacturing market. Viral vectors play a crucial role in T-cell engineering, particularly for cancer immunotherapy. Additionally, the development of COVID-19 vaccines utilizing viral vector platforms has significantly boosted demand.

Market Restraints

One of the major challenges in viral vector manufacturing is production capacity constraints. The high cost associated with gene therapies and the complexity in optimizing downstream processing also pose significant barriers to market growth.

Market Opportunities

The growing focus on expanding manufacturing facilities presents lucrative opportunities. Companies are partnering with research institutions to enhance viral vector technologies. Emerging economies offer vast potential due to increased investments in biotechnology and healthcare infrastructure.

Reasons to Buy the Report

✔ Comprehensive Market Analysis - Gain insights into market trends, growth factors, and challenges.
✔ Competitive Landscape - Understand strategies adopted by key players in the industry.
✔ Regional Insights - Identify high-growth regions and investment opportunities.
✔ Market Forecast - Get accurate projections on market size and growth rate till 2032.
✔ Emerging Trends - Stay ahead with updates on technological advancements and new developments.

Company Insights

Key Players in the Market

Thermo Fisher Scientific Inc.

Waisman Biomanufacturing

Creative Biogene

Sirion Biotech GmbH

Charles River Laboratories (Cobra Biologics)

GenScript ProBio

Recent Developments

In February 2022, SIRION Biotech partnered with the Centre for Genomic Regulation to develop novel adeno-associated viral vectors for gene therapy targeting diabetes.

In August 2022, Thermo Fisher Scientific launched a new viral vector manufacturing facility in Massachusetts to enhance cell and gene therapy production.

The viral vector manufacturing market is experiencing rapid growth, driven by advancements in gene therapy, vaccine development, and cell-based immunotherapies. As the industry expands, companies are focusing on technological innovation, strategic partnerships, and infrastructure development to meet the rising demand for high-quality viral vectors.

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.